Elia B.
- Country
- Italy
- Department
- SC Ematologia
Research Overview
- An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi
- Phase 3 Randomized Study of Pirtobrutinib, Venetoclax, and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- MARSUN: Phase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma
Data & Insights
Has run more than one trial at 18 of 134 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of marginal zone lymphoma, with particular focus on addressing cases that have shown resistance to conventional therapies.
- Lymphoma Management
- Refractory Disease Treatment
- Novel Therapeutic Combinations
Their research explores innovative treatment approaches for patients with relapsed or refractory conditions in the lymphoma spectrum.
Treatment Innovation
The investigator's work centers on evaluating combination therapy approaches in hematologic malignancies, particularly focusing on immunotherapy-based treatments.
- Targeted Therapy Development
- Immunotherapy Applications
- Treatment Response Assessment
Their expertise includes the evaluation of novel therapeutic combinations for improving patient outcomes in resistant disease states.
Clinical Assessment
The investigator utilizes advanced clinical assessment methodologies, including the application of Lugano criteria for evaluating treatment effectiveness in lymphoid malignancies.
- Disease Progression Monitoring
- Treatment Response Evaluation
- Survival Outcomes Assessment
Their work involves comprehensive evaluation of progression-free survival as a key metric in determining therapeutic efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.